|
Market Closed -
Nasdaq
04:00:00 20/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 840.84 USD | +3.78% |
|
+5.37% | +8.94% |
| 02:28am | Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition | MT |
| 02:04am | US FDA approves Regeneron's rare bone disorder drug | RE |
| Market Cap | 80.91B 69.4B 64.81B 59.46B 112B 7,733B 114B 765B 299B 3,878B 304B 297B 12,823B | P/E 2026 * |
18.8x | P/E 2027 * | 16.1x |
|---|---|---|---|---|---|
| Enterprise Value | 74.04B 63.51B 59.3B 54.41B 102B 7,077B 104B 700B 274B 3,549B 278B 272B 11,735B | EV / Sales 2026 * |
4.38x | EV / Sales 2027 * | 3.82x |
| Free-Float |
71.07% | Yield 2026 * |
0.48% | Yield 2027 * | 0.55% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +2.38% | ||
| 1 week | +5.37% | ||
| Current month | +10.26% | ||
| 1 month | +25.10% | ||
| 3 months | +33.40% | ||
| 6 months | +7.47% | ||
| Current year | +8.94% |
| 1 week | 792.57 |  | 844.92 |
| 1 month | 637.8 | | 844.92 |
| Current year | 591.52 | | 844.92 |
| 1 year | 541 | | 844.92 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/8/26 | Fiscal year | Director | 1,200 | 0.0012% | ||
| 10/8/26 | Fiscal year | Director | 2,400 | 0.0023% | ||
| 2/7/26 | Sell | Director | -200 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.78% | +5.37% | +47.06% | -0.42% | 80.91B | |
| +5.49% | +20.35% | -38.64% | -38.47% | 53.62B | |
| +0.85% | -4.04% | -2.31% | +30.25% | 50.13B | |
| +0.23% | -3.71% | +11.44% | +170.56% | 47.97B | |
| +4.24% | +6.08% | +59.56% | -16.41% | 31.41B | |
| +176.97% | +173.88% | +524.79% | +56.99% | 25.14B | |
| +4.05% | +6.38% | +50.33% | +98.01% | 25.03B | |
| +1.66% | +2.83% | -3.58% | +212.40% | 21.45B | |
| +0.22% | +5.48% | +65.69% | +127.79% | 16.93B | |
| +1.17% | +0.13% | +71.64% | +193.53% | 16.22B | |
| Average | +19.73% | +2.72% | +78.60% | +83.42% | 36.88B | |
| Weighted average by Cap. | +14.32% | +2.89% | +56.09% | +56.48% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.92B 14.52B 13.55B 12.44B 23.38B 1,617B 23.77B 160B 62.63B 811B 63.54B 62.15B 2,682B | 18.42B 15.8B 14.75B 13.54B 25.45B 1,760B 25.87B 174B 68.16B 883B 69.16B 67.65B 2,919B |
| Net income | 4.77B 4.09B 3.82B 3.51B 6.6B 456B 6.71B 45.12B 17.67B 229B 17.92B 17.53B 757B | 5.45B 4.67B 4.36B 4B 7.53B 520B 7.65B 51.47B 20.15B 261B 20.45B 20B 863B |
| Net Debt | -6.87B -5.89B -5.5B -5.05B -9.49B -656B -9.65B -64.92B -25.42B -329B -25.79B -25.23B -1,089B | -10.55B -9.05B -8.45B -7.76B -14.58B -1,009B -14.82B -99.75B -39.06B -506B -39.63B -38.77B -1,673B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/08/26 | US$840.84 | +3.78% | 748,839 |
| 18/08/26 | US$810.24 | +0.53% | 779,072 |
| 17/08/26 | US$805.93 | +0.30% | 541,306 |
| 14/08/26 | US$803.48 | -0.31% | 425,600 |
| 13/08/26 | US$805.97 | +1.00% | 709,747 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
